Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Smruthi Organics Ltd

Your Vote -

Buy

50.00%

Hold

25.00%

Sell

25.00%

50.00%

4 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Smruthi Organics Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Smruthi Organics posts Q1 net loss of Rs 1.10 cr

    13 Aug 2025, 2:00PM The company reported standalone net loss during the quarter stood at Rs 1.10 crore as compared to net loss of Rs 0.92 crore in the previous year quart
  • Smruthi Organics - Financial Results For The Quarter Ended 30Th June 2025

    13 Aug 2025, 1:34PM Financial Results for the first quarter ended 30th June 2025
  • Smruthi Organics - Board Meeting Outcome for Unaudited Quarterly Results For The First Quarter Ended 30Th June 2025

    13 Aug 2025, 1:28PM Unaudited Quarterly Results for the first quarter ended 30th June 2025
  • Smruthi Organics - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company Is Scheduled On 13/08/2025,I

    1 Aug 2025, 4:35PM Smruthi Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 ,inter alia, to consider and
  • Smruthi Organics has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025

    8 Jul 2025, 1:10PM As of June 2025, 64.73% is owned by Indian Promoters and 35.27% by Public. <p align=justify> Top five Promoters holding highest number of shares of Sm
  • Smruthi Organics - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    7 Jul 2025, 2:41PM Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30th June, 2025.
  • Smruthi Organics - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    20 Jun 2025, 4:13PM Scrutinizers Report and Voting results of AGM
  • Smruthi Organics - Shareholder Meeting / Postal Ballot-Outcome of AGM

    20 Jun 2025, 1:52PM Proceedings of 36th Annual general meeting
  • Smruthi Organics - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    20 Jun 2025, 4:13PM Scrutinizers Report and Voting results of AGM
  • Smruthi Organics - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    20 Jun 2025, 4:13PM Scrutinizers Report and Voting results of AGM

Key fundamentals

Evaluate the intrinsic value of Smruthi Organics Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 88.4287 81.3221 73.8533 70.0387 70.3877
Liabilities 88.4287 81.3221 73.8533 70.0387 70.3877
Equity 11.4463 11.4463 11.4463 11.4462 11.4462
Gross Profit 12.1822 11.9557 9.7806 18.4283 28.533
Net Profit 3.5629 3.5903 4.1309 10.3817 17.1074
Cash From Operating Activities 9.9762 4.4009 12.1051 1.91 22.8211
NPM(%) 2.82 2.81 2.92 7.78 13.52
Revenue 126.0079 127.6431 141.0409 133.3715 126.5007
Expenses 113.8257 115.6874 131.2603 114.9431 97.9677
ROE(%) 4.97 5.01 5.76 14.49 23.88

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Smruthi Organics Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 802.40 -0.20 73.05 92.46 301.39 0.62
Lotus Eye Hospital and Institute Ltd 118.65 -4.28 389.84 336.90 3.55 0.00
Bharat Immunological and Biologicals Corporation Ltd 22.25 2.53 0.00 699.52 -39.50 0.00
Astec Lifesciences Ltd 864.00 1.35 0.00 317.70 -604.77 0.00

Company Info

1995 -Smruthi Organics a bulk drug manufacturing company has decided to expand its product range by the introduction of Ciprofloxacin (antibiotic) and Ranitidine HCl. To part finance this project the company is entering the capital market on December 4th with a public issue of 18 88 550 lakh equity shares of Rs. 10 each at a premium of Rs. 5 per share. 2005 - The Company's Block No C and D being dedicated for exports and received 100% EOU status permission from the Development Commissioner, Seepz, Mumbai and started the activities. 2006 - The Company has created new facility i.e.; additional production plant viz. 'E' Block' at the Company's Factory No. Unit II Plot No A-27, MIDC, Chincholi, Solapur has commenced the commercial operation as an Export Oriented Unit. - The Board of Directors have recommended a dividend of 25% for the financial year. 2007 - The Company has been accredited the Current Good Manufacturing Practices - World Health Organization (cGMP - WHO) certificate from German Health Authorities (Landesamt fur Gesundheist and Soziales Berlin, Germany) for Active Pharmaceutical Ingredients (API) viz. Norfloxacin, Carbidopa and Metformin Hydrochloride for the European Union. 2009 - "Amlodipine Besilate (API)" has been granted Certificate of Suitability (COS) by European Directorate from the Quality of Medicines and Healthcare (EDQM). This recognition shall immensely help the Company to Enter EU Regulatory business in EU Countries. 2011 - Smruthi Orga - Manufacturing site U-II received USFDA approvals. - Recommendation of Dividend @ 25% on Equity Shares i.e. Rs. 2.50 per share. 2012 - The Board of Directors has recommended a dividend of 30% on Equity Shares of Rs. 10/- each for the year. 2021 -The Company has issued Bonus Shares in the Ratio of 2:1.

1995 -Smruthi Organics a bulk drug manufacturing company has decided to expand its product range by the introduction of Ciprofloxacin (antibiotic) and Ranitidine HCl. To part finance this project the company is entering the capital market on December 4th with a public issue of 18 88 550 lakh equity shares of Rs. 10 each at a premium of Rs. 5 per share. 2005 - The Company's Block No C and D being dedicated for exports and received 100% EOU status permission from the Development Commissioner, Seepz, Mumbai and started the activities. 2006 - The Company has created new facility i.e.; additional production plant viz. 'E' Block' at the Company's Factory No. Unit II Plot No A-27, MIDC, Chincholi, Solapur has commenced the commercial operation as an Export Oriented Unit. - The Board of Directors have recommended a dividend of 25% for the financial year. 2007 - The Company has been accredited the Current Good Manufacturing Practices - World Health Organization (cGMP - WHO) certificate from German Health Authorities (Landesamt fur Gesundheist and Soziales Berlin, Germany) for Active Pharmaceutical Ingredients (API) viz. Norfloxacin, Carbidopa and Metformin Hydrochloride for the European Union. 2009 - "Amlodipine Besilate (API)" has been granted Certificate of Suitability (COS) by European Directorate from the Quality of Medicines and Healthcare (EDQM). This recognition shall immensely help the Company to Enter EU Regulatory business in EU Countries. 2011 - Smruthi Orga - Manufacturing site U-II received USFDA approvals. - Recommendation of Dividend @ 25% on Equity Shares i.e. Rs. 2.50 per share. 2012 - The Board of Directors has recommended a dividend of 30% on Equity Shares of Rs. 10/- each for the year. 2021 -The Company has issued Bonus Shares in the Ratio of 2:1.

Read More

Parent Organisation

Smruthi Organics Ltd.

Founded

11/07/1989

Managing Director

Mr.Purushotham Eaga

NSE Symbol

FAQ

The current price of Smruthi Organics Ltd is

The 52-week high for Smruthi Organics Ltd is

The market capitalization of Smruthi Organics Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Smruthi Organics Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Smruthi Organics Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Smruthi Organics Ltd shares.

The CEO of Smruthi Organics Ltd is Mr.Purushotham Eaga, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT